The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2020 | Targeting BCL-2 in MDS
Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT, discusses agents targeting BCL-2 in the treatment of myelodysplastic syndromes (MDS), including luspatercept as well as an orally available version of decitabine. Dr Zeidan also highlights novel agents investigated in Phase I and II trials, including venetoclax in combination with azacitidine, which targets anti-apoptotic signals within cancer cells and shows promising activity in relapsed/refractory patients with MDS. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
